Clinical Outcome After Total Pancreatectomy With Islet Autotransplantation
Launched by LEIDEN UNIVERSITY MEDICAL CENTER · Mar 10, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients referred for TPIAT or TPIAT performed since 2014
- • Active and/or passive understanding of the Dutch language
- • Willingness to wear a FGM or CGM device at least in the 2 weeks prior to TPIAT, first 3 months after TPIAT and for 2 weeks before yearly clinical visits.
- Exclusion Criteria:
- • Known malignancies of the pancreas
About Leiden University Medical Center
Leiden University Medical Center (LUMC) is a prominent academic medical center located in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and high-quality patient care. As a clinical trial sponsor, LUMC focuses on translating scientific discoveries into effective therapies, fostering collaborations between researchers, clinicians, and industry partners. The center is dedicated to conducting rigorous clinical studies across various medical fields, ensuring adherence to ethical standards and regulatory requirements while prioritizing patient safety and outcomes. Through its multidisciplinary approach, LUMC aims to contribute significantly to the understanding and treatment of complex health conditions, driving progress in personalized medicine and improving global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leiden, Zuid Holland, Netherlands
Patients applied
Trial Officials
Prof. Eelco de Koning
Principal Investigator
LUMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials